The guide was launched last  5th  of May of 2017 at the European Commission’s third stakeholder event on biosimilar medicines, a discussion forum that provides a platform for stakeholders interested in biosimilars, including healthcare professionals, patients, payers, regulators and industry. The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally.

The main objective of this document is to increase, even more, the understanding of Biosimilar medicines by Healthcare proffesionals and also by all the stake holders involve as it was previously requested by Organisations from across the EU representing: doctors, nurses, pharmacists and patients have also shared useful views, to ensure that the guide adequately addresses questions relevant to healthcare professionals.

Dr Juan Garcia Burgos, Head of EMA’s Public Engagement Department, was in charge of the public presentation of the guide at launch, referring to the guide as: “this comprehensive reference material is a joint effort to support information and continuous education of healthcare professionals in the EU, and facilitate dialogue with patients.”

 

If you are interesting to check more information or download the Guide, please click on the links below:

NEW GUIDE IN BIOSIMILAR MEDICINES

EMA – PRESS RELEASE